<table id="t29" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>TableÂ 29: Clinically Important Drug Interactions with Latuda
</caption>
<col align="left" width="30.250%"></col>
<col align="left" width="69.750%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Strong CYP3A4 Inhibitors</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Clinical Impact:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Concomitant use of LATUDA with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone [<content stylecode="italics">see Clinical Pharmacology (<linkhtml href="#s165">12.3</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Intervention:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">LATUDA should not be used concomitantly with strong CYP3A4 inhibitors [<content stylecode="italics">see Contraindications (<linkhtml href="#s17">4</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Examples:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Moderate CYP3A4 Inhibitors</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Clinical Impact:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Concomitant use of LATUDA with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone [<content stylecode="italics">see Clinical Pharmacology (<linkhtml href="#s165">12.3</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Intervention:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 [<content stylecode="italics">see Dosage and Administration (<linkhtml href="#s13">2.6</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Examples:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Diltiazem, atazanavir, erythromycin, fluconazole, verapamil
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Strong CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Clinical Impact:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Concomitant use of LATUDA with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone [<content stylecode="italics">see Clinical Pharmacology (<linkhtml href="#s165">12.3</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Intervention:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">LATUDA should not be used concomitantly with strong CYP3A4 inhibitors [<content stylecode="italics">see Contraindications (<linkhtml href="#s17">4</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Examples:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Moderate CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Clinical Impact:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Concomitant use of LATUDA with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone [<content stylecode="italics">see Clinical Pharmacology (<linkhtml href="#s165">12.3</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Intervention:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">LATUDA dose should be increased when used concomitantly with moderate inducers of CYP3A4 [<content stylecode="italics">see Dosage and Administration (<linkhtml href="#s13">2.6</linkhtml>)</content>].
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Examples:
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">Bosentan, efavirenz, etravirine, modafinil, nafcillin
</td>
</tr>
</tbody>
</table>